JCR Pharmaceuticals Co., Ltd. (4552) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Sumitomo Pharma Co., Ltd.

Nippon Shinyaku Co., Ltd.

Tsumura & Co.

Hisamitsu Pharmaceutical Co., Inc.

Kyowa Kirin Co., Ltd.

Santen Pharmaceutical Co., Ltd.

Suzuken Co., Ltd.

JCR Pharmaceuticals Co., Ltd.

Kobayashi Pharmaceutical Co., Ltd.

SAWAI GROUP HOLDINGS Co., Ltd.

Taisho Pharmaceutical Holdings Co., Ltd.

Why is JCR Pharmaceuticals Co., Ltd. ?

The company has declared Negative results for the last 6 consecutive quarters

NET PROFIT(HY) At JPY -4,729 MM has Grown at -2,468.45%
NET SALES(HY) At JPY 15,761 MM has Grown at -8.89%
ROCE(HY) Lowest at -10.83%

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 12.20%, its profits have fallen by -199%

Underperformed the market in the last 1 year

The stock has generated a return of 12.20% in the last 1 year, much lower than market (Japan Nikkei 225) returns of 29.35%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to JCR Pharmaceuticals Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is JCR Pharmaceuticals Co., Ltd. for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

JCR Pharmaceuticals Co., Ltd.

6.71%

0.50

60.00%

Japan Nikkei 225

28.54%

1.14

25.81%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

5.94%

EBIT Growth (5y)

-216.09%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

0.45

Net Debt to Equity (avg)

0.53

Sales to Capital Employed (avg)

0.46

Tax Ratio

26.79%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.01%

ROCE (avg)

20.06%

ROE (avg)

13.01%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.63

EV to EBIT

-14.83

EV to EBITDA

-29.25

EV to Capital Employed

1.41

EV to Sales

3.07

PEG Ratio

Dividend Yield

ROCE (Latest)

-9.51%

ROE (Latest)

-11.65%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -0.18% (YoY

PRE-TAX PROFIT(Q)

At JPY -751 MM has Grown at 59.83%

NET PROFIT(Q)

At JPY -546 MM has Grown at 60.6%

-25What is not working for the Company

NET PROFIT(HY)

At JPY -4,729 MM has Grown at -2,468.45%

NET SALES(HY)

At JPY 15,761 MM has Grown at -8.89%

ROCE(HY)

Lowest at -10.83%

INTEREST(Q)

At JPY 79 MM has Grown at 51.92%

CASH AND EQV(HY)

Lowest at JPY 26,376 MM

DEBT-EQUITY RATIO (HY)

Highest at 58.2 %

Here's what is working for JCR Pharmaceuticals Co., Ltd.

Pre-Tax Profit

At JPY -751 MM has Grown at 59.83%

over average net sales of the previous four periods of JPY -1,869.5 MM

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (JPY MM)

Net Profit

At JPY -546 MM has Grown at 60.6%

over average net sales of the previous four periods of JPY -1,385.83 MM

MOJO Watch

Near term Net Profit trend is positive

Net Profit (JPY MM)

Raw Material Cost

Fallen by -0.18% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for JCR Pharmaceuticals Co., Ltd.

Interest

At JPY 79 MM has Grown at 51.92%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Net Sales

At JPY 15,761 MM has Grown at -8.89%

Year on Year (YoY)

MOJO Watch

Near term sales trend is negative

Net Sales (JPY MM)

Interest

Highest at JPY 79 MM

in the last five periods and Increased by 51.92% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Cash and Eqv

Lowest at JPY 26,376 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at 58.2 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio